scholarly journals A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects

2010 ◽  
Vol 33 (10) ◽  
pp. 1044-1052 ◽  
Author(s):  
Masahiro Fujino ◽  
Shin-ichiro Miura ◽  
Yoshihiro Kiya ◽  
Yukio Tominaga ◽  
Yoshino Matsuo ◽  
...  
Keyword(s):  
Molecular Structure ◽  
Angiotensin Ii ◽  
Small Difference ◽  
At1 Receptor ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Beneficial Effects ◽  
Receptor Blockers

scholarly journals CHALLENGES FOR GENERIC DRUG PRODUCERS

INDIAN DRUGS ◽  
2018 ◽  
Vol 55 (11) ◽  
pp. 5-6
Author(s):  
Nagaraj N. Rao ◽  
Keyword(s):  
Angiotensin Ii ◽  
Generic Drug ◽  
Generic Drugs ◽  
Global Market ◽  
At1 Receptor ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Regulated Markets ◽  
At1 Receptor Antagonists ◽  
Receptor Blockers

In the fiercely competitive global market for generic drugs, the complexities and interconnectivities come to the fore when a drug is recalled. In recent months, as you may be aware, the sartans (also known as AT1 receptor antagonists, angiotensin II receptor blockers/antagonists) have come into the limelight due to the recall of some of them from the regulated markets of USA and Europe.

The Impact of Angiotensin-II Receptor Blockers on Cardiovascular Events in Hypertensive Patients – Evidence from Real-life Databases

2010 ◽  
Vol 6 (3) ◽  
pp. 33
Author(s):  
Robert J Petrella ◽  
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Real World Setting ◽  
Actual Experience ◽  
Receptor Blockers ◽  
Randomised Controlled ◽  
The Impact

It is widely recognised that hypertension is a major risk factor for the development of future cardiovascular (CV) events, which in turn are a major cause of morbidity and mortality. Blood pressure (BP) control with antihypertensive drugs has been shown to reduce the risk of CV events. Angiotensin-II receptor blockers (ARBs) are one such class of antihypertensive drugs and randomised controlled trials (RCTs) have shown ARB-based therapies to have effective BP-lowering properties. However, data obtained under these tightly controlled settings do not necessarily reflect actual experience in clinical practice. Real-life databases may offer alternative information that reflects an uncontrolled real-world setting and complements and expands on the findings of clinical trials. Recent analyses of practice-based real-life databases have shown ARB-based therapies to be associated with better persistence and adherence rates and with superior BP control than non-ARB-based therapies. Analyses of real-life databases also suggest that ARB-based therapies may be associated with a lower risk of CV events than other antihypertensive-drug-based therapies.

Sign in / Sign up

Export Citation Format

Share Document